| 1. |
- Thompson, Paul M., et al.
(författare)
-
The ENIGMA Consortium : large-scale collaborative analyses of neuroimaging and genetic data
- 2014
-
Ingår i: BRAIN IMAGING BEHAV. - : Springer Science and Business Media LLC. - 1931-7557 .- 1931-7565. ; 8:2, s. 153-182
-
Tidskriftsartikel (refereegranskat)abstract
- The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA's first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Rahman, M., et al.
(författare)
-
The Ameliorating Effects Of Zingiber Zerumbet Linn On Sodium Arsenite-Induced Changes Of Blood Indices In Experimental Mice
- 2012
-
Ingår i: Life Sciences and Medicine Research. - : Aston Journals. - 1948-7886. ; , s. LSMR-41-
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this study was to evaluate the protective effect of Zingiber zerumbet Linn powder on sodium arsenite-induced changes of blood indices in experimental mice. Swiss albino male mice were divided into four groups. The first group was used as control, while the second, third and fourth groups were treated with Z. zerumbet (L.) powder, sodium arsenite and Z. zerumbet (L.) powder plus sodium arsenite, respectively. Animals (third and fourth groups) were exposed to sodium arsenite at a dose of 10 mg/kg body weight/day for 12 weeks. Exposure to sodium arsenite revealed a significant (p < 0.05) increase of serum urea, uric acid, triglyceride (TG), glucose levels and alkaline phosphatase (ALP) activity. Serum butyryl cholinesterase (BChE) activity significantly (p < 0.05) decreased in sodium arsenite-treated group as compared with control group. Interestingly, food supplemented with Z. zerumbet (L.) (50 mg/kg body weight/day) showed protective effect against sodium arsenite-induced increase of serum urea, uric acid and TG levels except serum glucose levels. Moreover, Z. zerumbet (L.) also abrogated the sodium arsenite-induced changes of BChE and ALP activities. Therefore, the ameliorating effects of Z. zerumbet (L.) on sodium arsenite-treated mice suggested the future application of Z. zerumbet (L.) to reduce or prevent arsenic toxicity in human.
|
|
